

Figure 2. Associations between numbers of HLA-associated mutation sites and CD4 cell count or viral load. A regression line is drawn in each graph: (A) shows the relationships with HLA-associated amino acid variations in the whole Gag sequence, and (B) shows the relationships with amino acid variations in p17, p24, and p2/p7/p1/p6.
 doi:10.1371/journal.pone.0011179.g002

reversion rate of these putative CTL escape mutations upon transmission to HLA-unmatched recipients varies considerably, suggesting that the rate of accumulation of CTL escape mutations in a given population differs substantially between mutations. Our data also suggest that the transmission of CTL-selected attenuated viruses is likely to confer a survival benefit on

HLA-unmatched recipients, at least during the early days of the infection.

These associations between HLA and viral sequences can be explained in several ways. The majority of associations are probably attributable to specific mechanisms by which the virus escapes from HLA-restricted, HIV-specific CTLs, such as loss of




Figure 3. Rates of reversion and mutation for each HLA-associated amino acid variant. HLA-associated mutation and reversion rates after viral transmission to contact spouses with distinct HLA profiles were calculated and plotted. Amino acid variations selected by non-dominant amino acid (●) and dominant amino acid (■) are shown. doi:10.1371/journal.pone.0011179.g003

peptide binding, loss of T-cell receptor recognition, and/or changes in peptide processing and presentation [1]. In fact, we found that two thirds of the HLA-associated variations were located within known CTL epitopes or their flanking regions. However, most previously reported CTL epitopes were identified in studies of other clades, indicating that these CTLs are probably cross-clade CTLs. Because studies of CTL epitopes in CRF01_AE infections are limited, we believe that several other mutations may occur in clade-specific CTL epitopes that have not yet been reported. Our current work on CTL epitope mapping using overlapping CRF01_AE Gag peptides has identified several new CTL epitopes, and at least two amino acid mutations have been found within the newly identified CRF01_AE Gag CTL epitopes (data are in preparation). Linkage disequilibrium can also explain the associations between HLA and viral sequences. There is a strong association between HLA_A*33 and _B*58 [22,23]. The A*33-associated T242X and G248X mutations are widely known to be selected by HLA_B*57/*5801 [26], so they are likely to be reflected in the linkage disequilibrium with B*58. Some HLA-associated mutations may also be part of the structural and functional compensatory mechanism underlying the development of primary CTL escape mutations, which can arise at sites considerably remote from the relevant epitopes [30].

This study has relatively low statistical power compared with previous studies. However, one of its strong aspects is that we identified a substantial number of HLA-associated amino acid variations that appear to be unique to a CRF01_AE-infected Thai population. Many of these variations do not appear in the list of HLA-associated mutations identified in subtype-B infections in over 1,500 subjects [15], and this cannot be explained by the relatively low statistical power of the present study. For instance, mutations such as S9X, V280X, and P453X had convincingly strong associations with HLA_B*13, _B*46, and _B*55, respec-

tively ($p < 0.001$; Table 1). However, none of these associations have been noted in subtype B, suggesting that there are a number of unidentified CTL pressures on Gag in the context of CRF01_AE infections in the Asian population. This indicates that an extensive search for CTL epitopes in various clades is warranted to facilitate the development of globally effective CTL vaccines.

Several publications have suggested that the Gag CTL response, as measured by interferon γ ELISPOT, has the most profound effect on the clinical outcome in subtype B and subtype C infections. Responses to the capsid protein are also likely to be most crucial in the containment of viral replication *in vivo* [31]. In this study, we have shown that variations in the capsid protein (p24) had the strongest association with viral load and CD4 cell count, indicating that regardless of the HIV clade, the p24 capsid is the most preferred target of HIV-1-specific CTLs. Therefore, p24 may be one of the important targets for effective CTL-based vaccines.

Reversion rates and mutation rates

When the virus is transmitted into a new host with a different HLA environment, the virus, which had already adapted to the previous host, must adapt again to the new HLA environment by reversion of the previous mutations and/or the creation of new mutations. One of the most interesting results of the present study is the variability in the reversion and mutation rates for each HLA-associated variant. We found that these rates varied considerably, depending upon the amino acid position, and that the reversion rate tended to correlate inversely with the mutation rate. It is plausible that an amino acid change with a low reversion rate tends to accumulate in the population, and that the rate of accumulation is higher if the mutation rate is higher and especially if its HLA allele is dominant. In fact, we found that all the

variations selected by dominant amino acid were associated with common HLA alleles and rarely changed from the consensus sequence, even after they were transmitted to HLA-unmatched recipients. These findings suggest that the viruses circulating within the population had already adapted to the common HLA alleles, resulting in best-fit sequences that could escape from those alleles. The results of our study will increase our understanding of the influence of immune pressure on HIV and on the future direction of virus evolution. Conversely, it is also plausible that an amino acid change with a high reversion rate, presumably with a functional or structural constraint at that position, is unlikely to accumulate rapidly in the population. It will be important for future CTL vaccine development to consider whether an escape mutant will accumulate or not. Therefore, further studies of this kind are required to provide valuable insights for future vaccine design.

T242N issues

This is the first report indicating that the p24 T242N escape mutation from the B*57/*58 CTL has a significant impact on the HIV-1 viral load in CRF01_AE infections and that the mutations, H219 and M228, compensate for the crippling effect of T242N. Although this is a rather predictable result because the TW10 site is conserved throughout the HIV-1 clades, it increases our insight. Two other dominant CTL epitopes within the capsid protein are restricted by B*57 (IW9: ISPRTLNAW; KF11: KAFSPEVPMF). However, the founder virus of CRF01_AE has a well-described 'peptide-processing mutation' at IW9 that affects the epitope presentation on HLA class I molecules, and a well-described CTL escape mutation within KF11 [33]. In fact, 100% of the CRF01_AE sequences in our cohort carried these amino acid substitutions (data not shown; see the Methods, for the GenBank accession number), indicating that these two CTL epitopes are less likely recognized in CRF01_AE infections. Several lines of evidence indicate that TW10 is the most important target determining the viral load set point: TW10 is the earliest target during primary infection [32]; and among all the described HLA-associated mutations, T242N is the earliest escape mutation that emerges during acute infections [13]. In light of these previously reported data and the nature of the CRF01_AE sequence, it would be interesting to determine whether TW10 is sufficient to protect B*57/*5801-positive subjects from disease progression. Unfortunately, we saw no clear protective effect of B*57/*5801 in the cohort reported here. However, as shown by the low median CD4⁺ T-cell count, our cohort was substantially advanced in terms of disease progression. Therefore, the accumulated compensatory mutations might have masked the true protective effect of B*57/*5801. Supporting this explanation, we observed substantially lower plasma viral loads in the B*57/*5801-positive subjects with T242N but without the compensatory mutations ($p=0.012$ by ANOVA; Figure 4).

We have also shown that the transmission of virus crippled by T242N might be associated with lower plasma viral loads in HLA-unmatched recipients, supporting a previous study of clade C infections [34]. However, the long-term effects of the transmission of virus attenuated by CTL escape mutations remain unknown and these contact cases should be examined longitudinally to determine whether virological escape accompanies the reversion of the T242N escape mutation.

Limitations

One of the limitations of this study is that we had no information regarding the timing of HIV transmission within the couples, although the rate of mutation is known to depend on the




Figure 4. Lower plasma viral loads in B*57/*5801-positive subjects with T242N. Plasma viral loads of patients grouped by the presence or absence of B*57/*5801 with T242N with or without the compensatory H219 and M228 mutations. doi:10.1371/journal.pone.0011179.g004

time from transmission [35]. However, perhaps because the duration of marriage in our discordant couples was quite long (median of seven years), we detected negligible amino acid changes between the first and second samplings. Therefore, we believe that most of the associations between amino acid mutations and HLA alleles observed in this study occurred in chronic infections. Another limitation is that this type of analysis depends heavily on statistical power. Therefore, it is difficult to identify HLA-associated variations if the allele frequencies and rates of mutation are low. Moreover, we did not use multiple testing corrections because of the small sample size, so we must admit there would have been a substantial number of false positive results. However, the high odds ratios of some of the novel HLA-associated mutations in the context of CRF01_AE infections in this Asian population strongly encourage us to obtain more information about CTL epitopes in different geographical regions where distinct HIV clades circulate, to develop globally effective CTL-based vaccines.

Our contact cases were not incident cases. Inevitably, there is also concern that the estimated direction of viral transmission was not true. However, because the HIV epidemic in Thailand started with commercial sex workers transmitting to their male clients and then from husbands to their wives [16], and partly because our study was conducted in a hospital close to a rural community, our interviews clearly indicated which spouse displayed risk behavior for HIV infection in most couples.

In conclusion, our data suggest two points: (a) HLA-associated amino acid mutations and CTL selection pressure on the p24 antigen appear to have the most significant impact on HIV replication in this CRF01_AE infection in an Asian population; and (b) the rates of accumulation of CTL escape mutations at the population level differ substantially between escape mutations, because the reversion rates varied considerably among the HLA-associated mutations.

Supporting Information

Figure S1 The inserted box magnifies the phylogenetic tree to show how the couples were identified.

Found at: doi:10.1371/journal.pone.0011179.s001 (0.48 MB TIF)

Table S1 The codon-based analysis demonstrated selection sites in the Gag protein.

Found at: doi:10.1371/journal.pone.0011179.s002 (0.28 MB XLS)

Table S2 Sequence mutation or reversion list.

Found at: doi:10.1371/journal.pone.0011179.s003 (0.04 MB XLS)

References

- Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. *Nat Rev Immunol* 4: 630–640.
- Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. *Nat Immunol* 5: 233–236.
- Reerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* 361: 2209–2220.
- McMichael AJ, Hanke T (2003) HIV vaccines 1983–2003. *Nat Med* 9: 874–880.
- Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? *J Exp Med* 205: 7–12.
- Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. *J Virol* 81: 10209–10219.
- Stephens HA (2005) HIV-1 diversity versus HLA class I polymorphism. *Trends Immunol* 26: 41–47.
- Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* 3: 205–211.
- Furutuki T, Hosoya N, Kawana-Tachikawa A, Tomizawa M, Odawara T, et al. (2004) Frequent transmission of cytotoxic-T-lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population. *J Virol* 78: 8437–8445.
- Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. *Nat Med* 3: 212–217.
- Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. *Science* 296: 1439–1443.
- Kawashima Y, Pfafferoth K, Frater J, Matthews P, Payne R, et al. (2009) Adaptation of HIV-1 to human leukocyte antigen class I. *Nature* 458: 641–645.
- Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, et al. (2008) Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. *J Virol* 82: 9216–9227.
- Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, et al. (2007) Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. *PLoS Pathog* 3: e94.
- Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, et al. (2009) HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. *PLoS One* 4: e6687.
- Ruxrungtham K, Brown T, Phanuphak P (2004) HIV/AIDS in Asia. *Lancet* 364: 69–82.
- Lau KA, Wang B, Saksena NK (2007) Emerging trends of HIV epidemiology in Asia. *AIDS Rev* 9: 218–229.
- Wichukhinda N, Kitamura Y, Rojanawiwat A, Nakayama EE, Song H, et al. (2007) The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection. *AIDS Res Hum Retroviruses* 23: 686–692.
- Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. *Brief Bioinform* 5: 150–163.
- Pond SL, Frost SD, Grossman Z, Gravenor MB, Richman DD, et al. (2006) Adaptation to different human populations by HIV-1 revealed by codon-based analyses. *PLoS Comput Biol* 2: e62.
- Pond SL, Frost SD, Muse SV (2005) HyPhy: hypothesis testing using phylogenies. *Bioinformatics* 21: 676–679.
- Fongsatikul L, Nantachit N, Kamtorn N, Leetrakool N (1997) HLA gene frequencies of northern Thais. *J Med Assoc Thai* 80 Suppl 1: S38–42.
- Romphruk A, Burusrux S, Puapairoj C, Urwijitaroon Y, Leelayuwat C (1996) Distribution of HLA-A and B antigens in northeastern-Thais. *J Med Assoc Thai* 79: 732–736.
- Nicole Frahm BB, Christian Brander (2008) Identification and optimal definition of HIV-derived cytotoxic T lymphocyte (CTL) epitopes for the study of CTL escape, functional avidity and viral evolution. In: Bette TM, Korber CB, Barton FHaynes, RichardKoup, John PMoore, Bruce DWalker, David IWatkins, eds. *HIV Molecular Immunology 2008*. Los Alamos, New Mexico: Los Alamos National Laboratory, Theoretical Biology and Biophysics. pp 3–24.
- Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007) Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. *J Virol* 81: 12608–12618.
- Martinez-Picado J, Prado JG, Fry EE, Pfafferoth K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J Virol* 80: 3617–3623.
- Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, et al. (1996) Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. *AIDS Res Hum Retroviruses* 12: 1691–1698.
- Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, et al. (2008) Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. *PLoS Pathog* 4: e1000033.
- Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, et al. (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. *J Exp Med* 205: 1009–1017.
- Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. *J Virol* 81: 12382–12393.
- Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. *J Virol* 80: 3122–3125.
- Altfeld M, Kalife ET, Qi Y, Streeck H, Lichtenfeld M, et al. (2006) HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. *PLoS Med* 3: e403.
- Matthews PC, Leslie AJ, Katzourakis A, Crawford H, Payne R, et al. (2009) HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering. *J Virol* 83: 4605–4615.
- Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, et al. (2007) CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. *J Virol* 81: 2440–2448.
- Leslie AJ, Pfafferoth KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. *Nat Med* 10: 282–289.

Acknowledgments

We would like to thank Dr Pokrath Hansasuta for helpful discussions and advice, and Dr Sitaya Sirisinha for valuable advice on the manuscript. We also thank Mr Sittichai Umnajsirikus, Ms Kanha Loryont, Mr Wicharn Khaekanha, and Mr Somchai Niyomthai for laboratory support at Lampang Hospital and Ms Phattaraporn Orataiwun, Ms Suthira Kasemsuk, Ms Sripai Saneewong-na-Ayuthaya, Ms Katkaew Thamachai, Ms Anongnard Suyasarojna, Ms Nutira Boonna, and Mr Praphan Wongnamngong for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: PA AT KA. Performed the experiments: GG NW BS. Analyzed the data: GG MM TS TM KA. Contributed reagents/materials/analysis tools: WA BS PP PS. Wrote the paper: MM TM AT KA. Clinical evaluation and patient recruitment: PP. Critical review: TM PA.

Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers[∇]

Toshiyuki Miura,^{1,2,3,4}* Zabrina L. Brumme,^{1,2,5,6}§ Mark A. Brockman,^{1,2,5,6} Pamela Rosato,¹ Jennifer Sela,¹ Chanson J. Brumme,¹ Florencia Pereyra,^{1,2} Daniel E. Kaufmann,^{1,2} Alicja Trocha,^{1,3} Brian L. Block,^{1,2} Eric S. Daar,⁷ Elizabeth Connick,⁸ Heiko Jessen,⁹ Anthony D. Kelleher,¹⁰ Eric Rosenberg,^{1,2} Martin Markowitz,¹¹ Kim Schafer,¹² Florin Vaida,¹³ Aikichi Iwamoto,⁴ Susan Little,¹² and Bruce D. Walker^{1,2,3,*}

Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts¹; Harvard University Center for AIDS Research, Boston, Massachusetts²; Howard Hughes Medical Institute, Chevy Chase, Maryland³; Division of Infectious Diseases, Advanced Clinical Research Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan⁴; Simon Fraser University, Burnaby, BC, Canada⁵; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada⁶; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California⁷; University of Colorado Denver, Division of Infectious Diseases, Aurora, Colorado⁸; Jessen-Praxis, Berlin, Germany⁹; National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW, Australia¹⁰; Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York¹¹; Department of Medicine, University of California at San Diego, San Diego, California¹²; and Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California at San Diego, San Diego, California¹³

Received 6 February 2010/Accepted 12 May 2010

Human immunodeficiency virus type 1 (HIV-1) controllers maintain viremia at <2,000 RNA copies/ml without antiretroviral therapy. Viruses from controllers with chronic infection were shown to exhibit impaired replication capacities, in part associated with escape mutations from cytotoxic-T-lymphocyte (CTL) responses. In contrast, little is known about viruses during acute/early infection in individuals who subsequently become HIV controllers. Here, we examine the viral replication capacities, HLA types, and virus sequences from 18 HIV-1 controllers identified during primary infection. *gag-protease* chimeric viruses constructed using the earliest postinfection samples displayed significantly lower replication capacities than isolates from persons who failed to control viremia ($P = 0.0003$). Protective HLA class I alleles were not enriched in these early HIV controllers, but viral sequencing revealed a significantly higher prevalence of drug resistance mutations associated with impaired viral fitness in controllers than in noncontrollers (6/15 [40.0%] versus 10/80 [12.5%], $P = 0.018$). Moreover, of two HLA-B57-positive (B57⁺) controllers identified, both harbored, at the earliest time point tested, signature escape mutations within Gag that likewise impair viral replication capacity. Only five controllers did not express “protective” alleles or harbor viruses with drug resistance mutations; intriguingly, two of them displayed typical B57 signature mutations (T242N), suggesting the acquisition of attenuated viruses from B57⁺ donors. These data indicate that acute/early stage viruses from persons who become controllers have evidence of reduced replication capacity during the initial stages of infection which is likely associated with transmitted or acquired CTL escape mutations or transmitted drug resistance mutations. These data suggest that viral dynamics during acute infection have a major impact on HIV disease outcome.

Human immunodeficiency virus type I (HIV-1)-infected individuals who control viremia spontaneously without antiviral therapy have been termed HIV controllers (3, 18, 21, 48, 52).

Unraveling the mechanisms associated with this phenotype should provide important insights regarding HIV pathogenesis and could contribute to vaccine development.

Host and viral genetics, as well as host innate and adaptive immune responses, influence the rate of disease progression in HIV-1 infection (reviewed in reference 18). Several studies have reported the correlation between *in vitro* HIV replication capacity and level of plasma virus loads or disease progression in individuals with chronic infection (6, 13, 35, 45, 50, 55). Studies of HIV-1 elite controllers (EC), who control viremia to below the limit of detection in commercial assays, have revealed the presence of replication-competent viruses in these individuals (7), although these viruses appear to be less fit based on studies of envelope (35) and Gag-protease (45). This

* Corresponding author. Mailing address for Bruce D. Walker: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, 149 13th St., Room 5212, Charlestown, MA 02129. Phone: (617) 724-8332. Fax: (617) 726-4691. E-mail: bwalker@partners.org. Mailing address for Toshiyuki Miura: Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5338. Fax: 81-5449-5427. E-mail: miura523@ims.u-tokyo.ac.jp.

§ These authors contributed equally.

∇ Published ahead of print on 26 May 2010.

fitness defect in the chronic phase of infection is due to at least in part to fitness-impairing mutations induced by cytotoxic-T-lymphocyte (CTL) responses restricted by "protective" HLA class I alleles (46).

In contrast, little is known about viruses obtained from the acute/early phase of infection in persons who subsequently become HIV-1 controllers, largely due to the difficulty in enrolling such people during the acute/early phase of infection. The characterization of acute/early-phase viruses in individuals who subsequently achieve low set-point virus loads is of paramount importance to our understanding of the mechanisms of HIV-1 control.

In the present study, we analyzed acute/early-phase plasma HIV RNA sequences from 18 untreated individuals who were diagnosed during the acute/early phase and subsequently became controllers (<2,000 RNA copies/ml). We compared these to sequences from a group of HIV-1 noncontrollers enrolled similarly during acute/early infection. We also generated chimeric viruses carrying patient-derived *gag-protease* sequences from acute/early-phase infection and compared the viral replication capacities of the chimeric viruses from controllers and from noncontrollers.

We observed that the chimeric viruses derived from controllers have significantly reduced replicative capacities compared to those from noncontrollers. Moreover, we observed that at least 80% of these individuals who go on to become controllers featured transmission of attenuated drug-resistant viruses, transmission of HLA-B57-restricted CTL escape variants to HLA-mismatched recipients, selection of attenuated CTL escape variants in HLA-B57-positive (B57⁺) recipients, or combinations of these factors. Taken together, these results indicate that the initial viral dynamics have a major influence on the subsequent course of disease.

MATERIALS AND METHODS

Study subjects and blood sample collection. All study participants were diagnosed during acute/early infection and remained untreated for a minimum of 1 year. Acute/early infection was defined according to published criteria (Acute Infection, Early Disease Research Program [AIEDRP] sponsored by NIAID) (28, 33). HIV controllers after primary infection (C-PI) were defined as HIV-1-infected subjects with acute/early infection who subsequently controlled viremia to less than 2,000 RNA copies/ml without antiviral treatment on at least 3 determinations over at least a 12-month period. Plasma and peripheral blood mononuclear cells (PBMC) from 18 C-PI were collected from multiple sites in the United States and Australia. Samples for 17 of these were obtained through the AIEDRP network. An additional subject (C-PI_13) was recruited at Massachusetts General Hospital. For individuals recruited through the AIEDRP network, the estimated date of infection (EDI) was calculated according to the AIEDRP criteria (37). For comparison, a group of 80 noncontrollers diagnosed during acute/early infection (noncontrollers after primary infection [NC-PI]) who failed to subsequently control viremia were drawn from AIEDRP and a previously described multicenter cohort with sites in the United States, Australia, and Germany (11). The participants from outside the AIEDRP network were subcategorized according to AIEDRP criteria as well. Written informed consent was obtained from all participants. The current study was approved by the appropriate institutional review boards, including that of Massachusetts General Hospital.

HLA typing. Human leukocyte antigen (HLA) class I typing of C-PI was determined using an in-house sequence-based method involving locus-specific nested PCR on extracted DNA from plasma or PBMC, followed by DNA sequence analysis and allele interpretation (12). HLA typing of NC-PI was performed as previously described (11).

Viral RNA isolation, reverse transcription-PCR, and sequencing. One to 3 ml of plasma from C-PI (or 0.5 ml for NC-PI) was centrifuged at 14,000 rpm (20,800 × g) for 2 h at 4°C, and viral RNA was extracted using a Qiagen viral

RNA blood mini kit (Qiagen, Inc.). Reverse transcription-PCR and sequencing were performed as described previously (44). Briefly, nested reverse transcription-PCR was attempted for all HIV coding sequences from C-PI but only for *gag* and *pol* from NC-PI, such that comparisons between the groups were limited to these sequences. Bidirectional population ("bulk") DNA sequencing was performed on an ABI 3730xl automated DNA sequencer. Data were analyzed using Sequencher software (Gene Codes). If the secondary peak was observed in both the 5' and 3' direction readings and the height of the secondary peak exceeded 25% of the dominant peak height in at least one of the two sequences, the nucleotides were interpreted to exist in mixtures at that position. Multiple alignment was performed using ClustalW. Contamination and/or sample mix-ups were ruled out by constructing a maximum-likelihood phylogenetic tree (DNAMl incorporated in BioEdit). Viral subtypes were determined using entire *gag* sequences with REGA HIV-1 Subtyping Tool version 2.0, available through the Stanford HIV Drug Resistance Database (<http://dbpartners.stanford.edu/RegaSubtyping/>). Likewise, drug resistance mutations were examined using the HIVdb Program Sequence Analysis tool (http://hivdb.stanford.edu/pages/algs/sierra_sequence.html).

Generation of chimeric viruses. Generation of *gag-protease* chimeric NL4-3 viruses, viral titration, and the replication capacity assay were performed as described previously (45). Briefly, *gag-protease* reverse transcription-PCR amplicons were cotransfected with linearized Δ *gag-protease* pNL4-3 vector into a long terminal repeat (LTR)-driven green fluorescent protein (GFP) reporter T cell line of CEM origin (GXR cells) (10), and chimeric viruses were obtained by homologous recombination. The patient origins of the resulting chimeric virus stocks were verified by comparing their sequences to the original plasma HIV RNA sequences (not shown). Titration was performed by infecting GXR cells with the chimeric viruses and measuring GFP expression by flow cytometry. The titer data were used to adjust input viral volumes in the subsequent replication capacity assay to obtain a multiplicity of infection (MOI) of 0.002 on day 2. GFP expression was monitored daily for a week. Replication capacity was expressed as the slope of the natural log of the percentage of GFP-expressing cells between days 3 and 6. Replication capacity assays were performed in duplicate, examining all of the viruses at the same time, and the average of the relative value to that of wild-type NL4-3 virus for each subject was used for comparisons.

Statistical analysis. Statistical analyses of continuous variables were performed using the Mann-Whitney U test. Comparisons of categorical value were performed using Fisher's exact test. A *P* value of <0.05 was considered statistically significant.

Nucleotide sequence accession numbers. Plasma viral sequences obtained in this study were submitted to GenBank under accession numbers GU367395 to GU367447 and GU367449 to GU367592.

RESULTS

Kinetics of plasma viremia during primary infection in persons who become HIV controllers. Little is known about the levels and kinetics of viremia during acute/early infection among individuals who subsequently become HIV-1 controllers. To address this, we identified 18 subjects diagnosed at the time of primary infection who maintained viral loads of <2,000 RNA copies/ml for at least a year in the absence of therapy (HIV controllers after primary infection [C-PI]). For each of these subjects, longitudinal samples were available for analysis of the kinetics of plasma viral load following untreated primary infection.

As shown in Fig. 1A and B, these 18 subjects achieved HIV control within 200 days after the estimated date of infection (EDI); they were then followed for a median of 1,089 (range, 744 to 2,079) days. Six of the 18 C-PI subsequently achieved elite control (<50 RNA copies/ml for at least 1 year) during follow-up (Fig. 1A), and 12 of the C-PI controlled viremia at between 50 and 2,000 RNA copies/ml (Fig. 1B). For those who achieved elite control, the time to viral loads of less than 50 RNA copies/ml varied widely. One subject was diagnosed with early infection at 130 days post estimated date of infection (EDI), when the viral load was already less than 50 RNA




FIG. 1. Kinetics of plasma virus loads during acute/early phase of infection in individuals who subsequently achieve viremia control (<2,000 RNA copies/ml). (A) Data for six controllers after primary infection (C-PI) who achieved elite control (EC; <50 RNA copies/ml) during the follow-up period. Each line represents the plasma virus loads of an individual patient; the dashed line indicates 2,000 RNA copies/ml. The blue line shows data for C-PI_18, who achieved <50 RNA copies/ml after 600 days post-EDI and, therefore, displayed >50 RNA copies/ml during the period shown in the figure. (B) Data for twelve C-PI who remained viremic during the follow-up period. Each line represents the plasma virus loads of an individual patient; the dashed line indicates 2,000 RNA copies/ml. VC, viremic controllers. (C) Data for C-PI_12, who achieved elite control after 700 days post-EDI after experiencing a blip in viremia. (D) Data for C-PI_04, who achieved elite control after 470 days post-EDI and also experienced virologic escape after 1,500 days post-EDI. (E and F) Data for C-PI_02 and 03, who experienced virologic escape. ART, antiretroviral therapy.

copies/ml, and another achieved persistently undetectable viral loads at day 170, whereas another subject (C-PI_18) achieved elite control relatively slowly (604 days post-EDI; data not shown). One subject (C-PI_12) initially achieved a stable viremia of less than 2,000 RNA copies/ml until 710 days, at which point there was a blip in viremia and then a decline to below the limits of detection (<50 RNA copies/ml) (Fig. 1C). During the average-3-year follow-up, only 3 of the 18 subjects lost control, as evidenced by an increase in viral load to over 2,000 RNA copies/ml (Fig. 1D, E, and F), including one person

initially meeting the criteria for elite control (C-PI_04) (Fig. 1D).

While the mean viral loads during acute infection have been reported to be in excess of 5×10^6 RNA copies/ml in other studies (31), the virus loads during acute phase in the HIV controllers studied here never exceeded 1×10^6 RNA copies/ml (Fig. 1A and B). Although it is important to note that the magnitude and timing of acute-phase peak viremia were likely not identified in most cases (as is also the case with other published studies), these observations nevertheless suggest




FIG. 2. Proportions of the individuals expressing protective HLA class I alleles. (A) Proportions of individuals expressing HLA-B57 among controllers after primary infection (C-PI), noncontrollers after primary infection (NC-PI), and chronic HIV controllers (C-chronic). (B) Proportions of individuals expressing protective HLA class I alleles (B13, B27, B51, and B57/B*1516/B*1517/B*5801) among C-PI, NC-PI, and C-chronic.

that persons who are able to control HIV spontaneously following primary infection may have lower levels of viremia during acute infection. These data indicate that viremia control can be initiated during the acute/early phase of infection and that when early control is achieved, it is largely maintained over the first few years of infection in persons who initially achieve this equilibrium. Moreover, they show that elite controller status may not be achieved until two or more years after primary infection.

HLA class I allele distribution in subjects who subsequently become HIV controllers. Among HIV controllers in the chronic phase of infection, there is an overrepresentation of “protective” HLA class I alleles, in particular, HLA-B57 and -B27 (4, 43, 48). To determine the potential role of host genetics in viral control in this cohort, we first performed high-resolution HLA typing. The frequency of individuals expressing HLA-B57 was the same in those who became HIV controllers (C-PI) as in those with primary infection who were defined as noncontrollers (NC-PI) (2/18 versus 5/80, $P = 0.6$) (Fig. 2A) but was lower than in an updated cohort of chronic HIV controllers (C-chronic [reference 48 and data not shown]) (224/719, $P = 0.074$). Likewise, the frequency of individuals expressing this and other so-called “protective” HLA class I alleles (defined as HLA-B13, -B27, -B51, and -B57/B*1516/B*1517/B*5801; see references 23, 25, 29, 32, and 47) among the C-PI did not differ from the frequency of such individuals among the NC-PI in the present study (5/18 versus 24/80, $P = 1.0$) (Fig. 2B) but, again, was significantly lower than in the chronic HIV controller cohort (5/18 versus 417/719, $P = 0.014$) (Fig. 2B).

Taken together, these data suggest that persons who achieve




FIG. 3. Replication capacities of chimeric NL4-3 viruses carrying *gag-protease* derived from the acute phase of infection in controllers and noncontrollers. Replication capacities were compared between clade B-infected C-PI ($n = 15$) and NC-PI ($n = 45$). Average results of duplicate experiments for each virus normalized to the replication capacity of wild-type (wt) NL4-3 virus were plotted (expressed as the slope of the natural log of viral spread between days 3 and 6; see Materials and Methods). (A) Data for all of the chimeric viruses derived from individuals in acute/early phase of infection. The pink dots indicate viruses carrying protease inhibitor (PI) resistance mutations. (B) Data are the same as in the analysis shown in panel A, but the data for viruses derived from the NC-PI are stratified according to phase of infection (acute or early). Horizontal lines show medians of the results.

viral control following acute/early infection differ in host genetics from those HIV controllers classified using chronic-phase clinical and phenotypic definitions in that they are not enriched for the usual protective alleles associated with chronic HIV control (23, 25, 29, 32, 47).

Chimeric NL4-3 viruses carrying *gag-protease* derived from individuals who go on to become HIV controllers display reduced replication capacities. Our finding that protective HLA alleles were not enriched in this group suggested that factors other than host genetics might influence early control of viremia and led us to examine viral factors that might contribute to enhanced control. We recently reported that chimeric NL4-3 viruses carrying *gag-protease* derived from chronic elite controllers display reduced replication capacities compared to the

TABLE 1. HLA class I alleles, viral antiretroviral drug resistance mutations, and B57 footprint profiles in early controllers

C-PI	HLA class I alleles ^c	HLA-B57 footprint ^d	Viral drug resistance mutation(s) to:		
			PI	NRTI	NNRTI
01	A25/A68/B18/ <u>B57</u> /Cw06/Cw12	T242N (I147L)	None	None	None
02	A02/A31/B08/B44/Cw05/Cw07	(I147L)	None	None	None
03	A01/A68/B08/B44/Cw05/Cw07	None	M46L, I54FL, I84V, N88D, L90 M	M41L, D67N, T69D, M184V, L210W, T215Y	A98G, K103N, Y318F
04	A26/A31/B07/B18/Cw07/Cw07	None	D30N, M46I, I84V, N88D, L90 M	M41L, E44D, D67N, K70R, L74I, V118I, L210Y, T215Y, K219Q	None
05	A01/A32/B35/B44/Cw02/Cw05	A146P (N252G)	None	None	None
06	A01/A01/ <u>B*1517</u> /B49/Cw07/Cw12	G248A A146N (I147 M)	None	D67N, T215S, K219E, G333E	None
07	A02/A02/B07/ <u>B*5801</u> /Cw07/Cw07	(G248E)	None	M41L	None
08	A03/A68/B14/B44/Cw07/Cw08	None	None	None	None
10	A23/A31/B39/B52/Cw07/Cw12	T242N A146P (I147L)	None	None	None
11	A01/A02/B44/ <u>B57</u> /Cw05/Cw06	T242N G248A (I147L)	None	None	None
12	A01/A31/B37/B51/Cw01/Cw06	(I147L) G248A (M250I)	None	None	None
13 ^a	A03/A31/B35/B35/Cw04/Cw04	N/D	None	None	None
14	A02/A32/B35/B44/Cw04/Cw05	None	None	M184V	G190A
15	A11/A31/B27/B35/Cw01/Cw01	(I147L)	None	None	None
16	A02/A29/B44/B49/Cw07/Cw16	NA	NA ^b	NA	NA
17	A02/A02/B44/B49/Cw07/Cw16	NA	NA	NA	NA
18	A02/A24/ <u>B*1501</u> /B41/Cw03/Cw17	None	None	None	K103N P225H
20	A02/A03/ <u>B*1501</u> /B56/Cw01/Cw03	T242N G248A (I147L)	None	None	None

^a Unique recombinant form on clade A backbone.

^b NA, not available.

^c HLA-B57 and analogues are underlined.

^d Mutations in parentheses are likely selected by HLA-B57.

replication capacities of those derived from chronic progressors (45). To determine the relative fitness of acute/early viruses in these subjects, we constructed chimeric *gag-protease* viruses from the earliest viral isolates from both C-PI and NC-PI subjects. In this analysis, *gag-protease* genes were amplified from plasma HIV RNA and chimeric viruses were generated for 15 subtype B-infected C-PI (C-PI₁₃ was infected with a unique recombinant form with a clade A backbone and, therefore, was excluded from the following analyses). As a control, we randomly chose 45 of the 80 NC-PI (median baseline virus load, 186,000 RNA copies/ml [interquartile range, 6,160 to 750,100]). As in previous studies (9, 45, 46, 53), replication capacity assays were performed and the slope of the natural log of viral spread in culture between days 3 and 6 was calculated. All viruses were assayed in the same experiment run in duplicate, and the results are presented as the values relative to the results for the wild-type NL4-3 virus.

As shown in Fig. 3A, chimeric viruses carrying *gag-protease* derived from individuals who go on to become controllers displayed significantly reduced replication capacities compared to those from individuals who became noncontrollers (C-PI versus NC-PI, 0.84 versus 0.98, $P = 0.0003$). Since many of the NC-PI were diagnosed during the acute phase of infection (AIEDRP group 1), whereas most of the C-PI were diagnosed during early infection (AIEDRP group 3), there was a concern that the observed difference might be a reflection of differences between acute and early infection. Therefore, we repeated the analysis, stratifying the 45 NC-PI into AIEDRP group 1 (acute, $n = 25$) or group 3 (early, $n = 20$), but found no statistically significant difference between them (0.95 versus 0.99, $P = 0.23$), whereas chimeric viruses carrying *gag-protease* from the C-PI displayed significantly reduced replication capacities

compared to the replication capacities of viruses from acute and early NC-PI ($P = 0.005$ and 0.0003 , respectively) (Fig. 3B). These data indicate that defects in viral fitness are strongly associated with the ability to control viremia following primary infection.

CTL escape mutations are present in viral sequences obtained from the acute/early phase in the persons who subsequently become HIV controllers. We recently reported that attenuation of the replication capacity of chimeric viruses carrying *gag-protease* derived from chronic elite controllers is associated with specific HLA class I alleles, indicating virus attenuation due to immune selection pressure (45). Since we observed the viruses in the C-PI to be attenuated, we next examined plasma viral sequences for evidence of CTL-driven escape mutations from the earliest available time point (median, 86 days, and range, 33 to 203 days post-EDI).

As shown in Tables 1 and 2, both C-PI expressing HLA-B57 (C-PI₀₁ and 11) harbored the B57-associated Gag T242N escape mutation within the TW10 (TSTLQEIQGW, Gag amino acids 240 to 249) epitope known to affect viral replication capacity (9, 22, 36, 40). One of the *gag* compensatory mutations, I223V, that is known to partially restore replication capacity impaired by the T242N mutation (9) was observed in C-PI₁₁, but none of these compensatory mutations was observed in C-PI₀₁ (Table 2). The relative replication capacities of chimeric NL4-3 viruses carrying *gag-protease* derived from these individuals were substantially reduced (0.864 and 0.724, respectively). Only one of the 45 NC-PI whose chimeric virus was tested for replication capacity expressed HLA-B57. The autologous viral sequence obtained at 59 days post-EDI exhibited the fitness-impairing T242N mutation but also the H219Q compensatory mutation, and the relative replication capacity

TABLE 2. Plasma viral Gag protein sequences in 15 clade B-infected early controllers^a

C-PI	HLA-B57 analogue	Mutation(s) in indicated part of Gag sequence ^a	
		133 PIVQNLQGQMVHQAISPRTLNAWVK 157	213 DRLHPVHAGPIAPGQMRPRGSDIAGTTSTLQEQIGWMTNNPPI 256
01	B57L.....N.....
02	NoneL.....	..T.....V...H....
03	NoneL.....S.....S....
04	None	..I.....A.....S.....
05	NoneI.....P.....Q...V.....G....
06	B*1517NM.....Q...V...I.....A...H....
07	B*5801L.....	..V.....E...S...A..
08	NoneL.....	..M.....S.....
10	NoneP.....L.....N.....
11	B57L.....V.....N.....A...S....
12	NoneL.....V.....A...I....
14	NoneM.....L.....S.....
15	NoneL.....M.....H....
18	NoneM.....L.....	..T.....N.....A.....
20	NoneL.....N.....A.....

^a CTL epitopes restricted by HLA-B57 [IW9 (ISPRTLNAW) and TW10 (TSTLQEQIGW)] and major B57 footprint sites in sequences from the C-PI are underlined.

of the chimeric virus derived from this subject was slightly reduced (0.852). Although this subject was categorized as an NC-PI, the plasma virus load was only 3,680 RNA copies/ml on day 59 post-EDI, indicating that viremia had been relatively well controlled in this subject. Taken together, the replication capacities of chimeric viruses carrying *gag-protease* obtained during acute infection from HLA-B57-positive subjects appeared moderately reduced, which might be attributable to the typical fitness-impairing T242N escape mutation.

Evidence of transmitted CTL escape mutants from HLA-B57⁺ donors. Recently, it was reported that individuals who acquired HIV from B57⁺ donors have a better clinical course at least during the first year of infection (15), suggesting that the acquisition of attenuated viruses may benefit the recipient even in the absence of the restricting protective allele. Therefore, we investigated whether some C-PI might have acquired viruses from donors expressing protective HLA alleles. Examining Gag protein sequences in the C-PI, we observed the signature B57 escape mutation T242N that compromises replication capacity (9, 40) in two of the 5 C-PI who expressed no other protective alleles (C-PI_10 and 20) (Tables 1 and 2), and there was a trend of a higher frequency of the T242N mutation in the C-PI than in the NC-PI (2/5 versus 4/47). The viruses in C-PI_10 also exhibited the A146P/I147L signature escape mutations within and flanking the B57 ISW9 epitope (Gag amino acids 147 to 155) (20), adding further evidence that the viruses were transmitted from a B57⁺ donor. The A146P/I147L mutations in conjunction with the T242N mutation have been shown to further reduce viral replication capacity (8). The relative replication capacity of the chimeric NL4-3 virus derived from C-PI_10 was extremely reduced (0.546), but the replication capacity of the virus derived from C-PI_20 was only minimally reduced (0.928). For C-PI_10, follow-up samples were available at 20 months after the EDI, but despite persistent low-level virus production *in vivo*, no reversions of B57-associated mutations (A146P/I147L/T242N) were observed (data not shown). These data suggest that transmission of viruses attenuated by CTL escape mutations in the HLA-B57⁺ donors may account for some of the C-PI and indicate that

transmitted CTL escape mutations may impair the replication capacity and pathogenicity of HIV following transmission.

High frequency of drug resistance mutations in plasma viral sequences in individuals who go on to become HIV controllers. Viral fitness can be impaired by defects in other HIV genes. In addition to *gag* sequences, we obtained plasma viral sequences for other HIV genes from the C-PI (16 *pol*, 14 *vif*, *vpr*, and *vpu*, 14 partial envelope, 11 *nef*, and 14 *rev* and *tat* sequences); however, similar to earlier studies of chronic elite controllers (44), virus sequencing in this cohort revealed no gross viral genetic defects (data not shown). Since selection pressures by antiretroviral drugs are known to impair viral replication capacity as well, we looked for the presence of “major” resistance mutations (as defined by the Stanford HIV Drug Resistance Database) in autologous viral sequences obtained during the acute phase of infection from the controllers and compared the frequency of these mutations to their frequency in sequences from noncontrollers.

Analysis of protease and reverse transcriptase (RT) sequences revealed a significantly higher prevalence of antiretroviral resistance mutations in C-PI (6/15 [40.0%]) than in NC-PI (10/80 [12.5%]) ($P = 0.018$) (Fig. 4A), some of which have been demonstrated to reduce viral replication capacity (M184V, L210W, T215Y, etc.) (26, 27, 39, 59). Among individuals who went on to become controllers, we observed two cases of protease inhibitor (PI) resistance mutations, 4 cases of nucleoside analogue reverse transcriptase inhibitor (NRTI) resistance mutations, and 3 cases of non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) resistance mutations (Table 1). In addition, three of these cases exhibited multiclass drug resistance, which was also significantly more frequent than in NC-PI (3/15 versus 1/80, $P = 0.012$) (Fig. 4B and Table 1). Notably, excluding individuals expressing protective HLA alleles, the frequency of individuals infected with drug-resistant strains reached 60% among C-PI versus 8.5% in NC-PI (6/10 versus 4/47, $P = 0.0035$) (Fig. 4C), and the frequency of multiclass drug resistance strains reached 30% (Fig. 4D). Taking into consideration that resistance mutations can negatively impact viral replicative capacity (17, 39, 56, 58), these results




FIG. 4. Proportions of individuals diagnosed during acute/early phase and carrying viral strains with major drug resistance mutations (see Materials and Methods) are shown. (A) Data for individuals infected with strains with major PI, NRTI, and NNRTI resistance mutations. (B) Data for individuals infected with multiclass drug-resistant strains. (C) Data for individuals without protective HLA class I alleles infected with strains with major PI, NRTI, and NNRTI resistance mutations. (D) Data for individuals without protective HLA class I alleles infected with multiclass drug-resistant strains.

suggest that the transmission of drug-resistant variants contributes to viremia control during the early phase of infection in these individuals. It is important to note that in the present study, we analyzed replication capacity only for *gag-protease* chimeric viruses and, thus, that resistance mutations within RT were not evaluated. Among the total 60 viruses tested for replication capacity, five viruses (2 from C-PI and 3 from NC-PI) carried PI resistance mutations (Fig. 3A). Except for one virus derived from an NC-PI, all displayed moderately to severely impaired replicative capacities: the relative replication capacities of viruses derived from the two C-PI were 0.760 (C-PI_03) and 0.575 (C-PI_04), and viruses from two of the NC-PI carrying PI resistance mutations were moderately impaired (0.875 and 0.842).

Follow-up *pol* sequences were available 6 months later from two C-PI, both of whom became viremic controllers (50 to 2,000 RNA copies/ml). No change in resistance profile was observed in subject C-PI_06, whereas in subject C-PI_03, four of the 9 initially documented RT resistance mutations (M184V, L210F, and T215Y for NRTI and Y318F for NNRTI) (Table 1) reverted to the wild type (data not shown). However, plasma viral loads remained low in both individuals.

In addition, we were able to obtain the plasma *pol* sequence from subject C-PI_04, who became an elite controller despite lacking protective HLA alleles but experienced virologic escape after 4 years of infection (Fig. 1D). At that time, 2 of the NRTI resistance mutations (K70R and L74I) had reverted to the wild type, and the T215Y mutation partially reverted to T215C/S when the plasma viral load rose to 1,300 RNA copies/ml around 5 years post-EDI. Although the L74I and T215Y mutations are known to affect viral replicative fitness only moderately (39), the K70R mutation in conjunction with the M41L mutation strongly attenuates virus (30), suggesting that these reversions may have contributed to the virologic escape in this case.

DISCUSSION

Here, we demonstrate that viruses from persons who spontaneously control HIV following primary infection show impaired replicative capacity in the earliest stages of infection, indicating that characteristics of the infecting virus have a significant impact on viral set point and virus-host dynamics. By constructing chimeric viruses expressing the *gag-protease* region of patient isolates and inserting them into a laboratory strain backbone, we show that viruses derived from persons who are able to achieve viral loads of less than 2,000 RNA copies/ml are attenuated compared to contemporaneous viruses derived from persons who go on to develop progressive infection. Of subjects confirmed to be infected with clade B virus, 12/15 (80%) were recipients of potentially attenuated drug-resistant strains or viruses selected in B57⁺ donors or expressed protective HLA alleles that selected for less fit viruses (summarized in Table 1). Remarkably, two cases had more than one factor: they expressed B57 analogues and were infected with NRTI-resistant strains. Together, these data indicate that viral dynamics in the earliest stages of HIV infection have a major impact on the course of disease.

In these persons who achieved viral control following primary infection, there was no enrichment of HLA alleles associated with long-term control found in chronic-controller cohorts. Instead, we saw enrichment for other factors that can attenuate virus replication, including transmission of drug-resistant strains and strains containing attenuating CTL escape mutations. The surprising finding that HLA-B57 was not enriched among controllers after primary infection may be related to the fact that persons expressing this allele are less symptomatic during acute infection and, thus, may have been less likely to be recognized and recruited in the acute phase of infection (1). Another important issue raised by this observation is the durability of control that is achieved early after acute

infection. Indeed, one C-PI who achieved elite control status but did progress later lacked protective HLA alleles. However, the majority of persons without protective alleles were able to persistently control viremia, in one case (C-PI_03) even after reversion of some of the drug resistance mutations, suggesting that early attenuation of virus may have sustained consequences. Additional follow-up will be required to answer this question.

The subjects in this study were largely selected from subjects enrolled in the Acute Infection, Early Disease Research Program, based on their ability to achieve controller status following documented primary infection. The criteria consisted of at least 1 year of viral loads of less than 2,000 RNA copies/ml, used to define HIV controllers because this is a level at which disease progression and transmission are much less likely (49). Of the 18 individuals who went on to become HIV controllers, 6 eventually met the criteria for elite control, with viral loads persisting at below 50 RNA copies/ml. Since one of the C-PI who achieved elite control (C-PI_04) and two C-PI who became viremic controllers (C-PI_02 and C-PI_03) later progressed, early control does not necessarily predict long-term control. Of note, none of them expressed protective HLA alleles, suggesting an important role of host genetics in eventual outcome.

Although we did not show any direct impact of individual mutations observed here on viral replicative capacity, there are several studies that demonstrate a fitness cost of PI resistance mutations in particular (41, 42, 60) and of CTL escape mutations within the Gag protein (9, 40, 53). Indeed, the viruses from two of the B57⁺ C-PI were carrying the T242N escape mutation. In addition to these, we found putative B57 footprint mutations in the individuals expressing HLA-B*1517 (C-PI_06) and HLA-B*5801 (C-PI_07) that are known to cross-present B57 TW10 epitopes (23, 36). The autologous viral sequence for C-PI_06 did not have any of the typical signature B57 footprint mutations A146P/I147L/T242N but contained the G248A mutation that is associated with HLA-B57. Uncommon substitutions at the sites associated with HLA-B57 (A146N/I147M) were also observed (Tables 1 and 2) (20, 36). Likewise, none of the typical signature B57 mutations A146P/I147L/T242N were seen in C-PI_07, but the autologous viral sequence displayed a rare mutation (G248E) that has been reported to be selected in B57⁺ subjects during primary infection (5). Although we do not have direct experimental evidence of a viral fitness cost due to these mutations, substitutions at these sites have been previously shown to impair viral replication capacity (8, 46). Indeed, the relative replication capacities of the chimeric NL4-3 viruses carrying *gag-protease* derived from these persons were reduced (0.887 and 0.658, respectively). Taken together, viruses in these 2 C-PI expressing HLA-B57 analogues likely harbored allele-specific mutations which might have contributed to compromised viral replication capacity.

We observed the typical HLA-B57 footprint mutation (T242N) in plasma viral sequences in two of the C-PI expressing none of the protective HLA alleles, supporting previous reports of better early clinical outcome of recipients who acquired viruses from B57-positive donors (15). By analyzing viral sequences in the rest of the C-PI, we found other mutations within and flanking the TW10 epitope that had likely

been selected in B57⁺ donors: autologous virus from C-PI_12 expressing the protective allele HLA-B51 had rare G248A/M250I mutations that were previously shown to be observed in B57⁺ chronic elite controllers and to impair viral replication capacity *in vitro* (46), and the replication capacity of the *gag-protease* chimeric NL4-3 virus derived from this person was reduced (0.843). Another non-B57 analogue subject (C-PI_05) harbored the B57 signature mutation A146P and a rare N252G mutation in the flanking region of the TW10 epitope that had been observed in a B57 elite controller and demonstrated to affect viral replicative capacity (46). However, the replication capacity of the chimeric NL4-3 virus for this person was not appreciably reduced (0.943). These data suggest that there were additional individuals who potentially acquired viruses from B57-positive donors and went on to become controllers.

In the current study, we did not examine the function of the reverse transcriptase or the impact of individual resistance mutations on RT function, but there are a number of publications that also support the theory presented here (19, 26, 27, 30, 38, 39, 57, 59). For instance, the M184V mutation observed in C-PI_03 and 14 is selected by lamivudine and is known to strongly reduce viral replicative fitness (39, 59); the T215Y mutation observed in C-PI_03 and 04 has a similar effect, albeit moderately (26, 39), and in addition, the L210W mutation that was observed in C-PI_03 and remained at the later time point has been shown to have a strong negative impact on viral replication capacity (27). Moreover, there was a report that the number of NRTI resistance mutations inversely correlates with viral replicative capacity (51), further supporting the idea that viruses from the acute phase of infection carrying multiple resistance mutations in some of the individuals who go on to become controllers are attenuated.

While the difference in replication capacities of chimeric viruses derived from the acute/early phase of infection in controllers and noncontrollers was significant, chimeric viruses derived from some controllers displayed only minimal reductions in replication capacity, suggesting that a better early clinical course cannot be explained solely by attenuation of Gag-Protease function. Impairment of HIV replication by mutations in other genes, like *nef* deletions (16, 34), or by other mechanisms may also be important. Therefore, it will be warranted to investigate the function of other HIV proteins, including RT and envelope, in future studies.

The hypothesis presented here, that viral attenuation affects the course of disease following acute infection, has been proposed previously (2, 35, 50) and is supported by other studies showing that the transmission of escape mutations selected by protective alleles in the donor provides a clinical advantage to the recipient (15, 24). Moreover, a recent study of children born to B57⁺ mothers revealed reduced viral loads in the B57⁺ children despite the transmission of B57 CTL escape mutants (54). In addition, there is a report of an inverse relationship between plasma viral load and the number of genotypic resistance mutations during primary infection (14). These data strongly suggest that the transmission of less fit viruses due to attenuating antiretroviral resistance mutations and CTL escape mutations could result in a favorable clinical course in the recipients, at least during the early phase of infection. It should be noted that our findings might imply that the spread of drug-resistant variants will increase the proportion of individ-

uals who can control viremia in the early phase of infection; however, further investigations are necessary in order to clarify this point.

In conclusion, viruses obtained during the acute/early phase of infection from persons who subsequently become controllers were attenuated. This observation can be partly explained by the transmission of drug-resistant strains and/or CTL escape variants from B57⁺ donors or by *de novo* CTL escape mutations in B57⁺ recipients. During an average of 3 years of follow-up, the plasma virus load remained stable in the majority of subjects, even in one in whom apparent fitness-enhancing reversions were observed. These data suggest that viral attenuation in acute infection may have a long-term impact on control, but further longitudinal studies are warranted to reveal the role of viral fitness in long-term control of HIV-1 infection.

ACKNOWLEDGMENTS

This work was supported by grants AI028568 and AI030914 (B.D.W.), AI55356 (E.C.), and AI041534 and AI047033 (M.M.) from the NIAID/NIH and by the Howard Hughes Medical Institute, the Harvard University Center for AIDS Research (HU CFAR), the Mark and Lisa Schwartz Foundation, the International AIDS Vaccine Initiative (IAVI), and the Bill and Melinda Gates Foundation. Z.L.B. is supported by a New Investigator Award from the Canadian Institutes for Health Research (CIHR). NCHECR is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, the University of New South Wales. A.D.K. is supported by an NHMRC Practitioner Fellowship.

Samples and data from Australia were collected through the Primary Infection network consisting of R. Finlayson, Taylor Square Clinic, Darlinghurst, NSW; M. Bloch, Holdsworth House, Darlinghurst, NSW; R. Macfarland, East Sydney Doctors, Darlinghurst, NSW; C. Workman AIDS Initiative, Darlinghurst, NSW; N. Roth, Prahan Market Clinic, Prahan, Victoria; and David Cooper, St. Vincent's Hospital, Darlinghurst, NSW.

We thank Mary Carrington and Yuko Yuki for HLA class I typing of a subset of the noncontrollers.

The ideas and opinions expressed in the manuscript are solely the responsibility of the authors and are not necessarily shared by the NIH or other funding sources, Massachusetts General Hospital, or its affiliates.

The authors declare no conflicts of interest related to this study.

REFERENCES

- Altfeld, M., M. M. Addo, E. S. Rosenberg, F. M. Hecht, P. K. Lee, M. Vogel, X. G. Yu, R. Draenert, M. N. Johnston, D. Strick, T. M. Allen, M. E. Feeney, J. O. Kahn, R. P. Sekaly, J. A. Levy, J. K. Rockstroh, P. J. Goulder, and B. D. Walker. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. *AIDS* 17:2581-2591.
- Arien, K. K., G. Vanham, and E. J. Arts. 2007. Is HIV-1 evolving to a less virulent form in humans? *Nat. Rev. Microbiol.* 5:141-151.
- Bailey, J. R., K. G. Lassen, H. C. Yang, T. C. Quinn, S. C. Ray, J. N. Blankson, and R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. *J. Virol.* 80:4758-4770.
- Bailey, J. R., T. M. Williams, R. F. Siliciano, and J. N. Blankson. 2006. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. *J. Exp. Med.* 203:1357-1369.
- Bailey, J. R., H. Zhang, B. W. Wegweiser, H. C. Yang, L. Herrera, A. Ahonkhai, T. M. Williams, R. F. Siliciano, and J. N. Blankson. 2007. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. *J. Infect. Dis.* 196:50-55.
- Blaak, H., M. Brouwer, L. J. Ran, F. de Wolf, and H. Schuitemaker. 1998. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. *J. Infect. Dis.* 177:600-610.
- Blankson, J. N., J. R. Bailey, S. Thayil, H. C. Yang, K. Lassen, J. Lai, S. K. Gandhi, J. D. Siliciano, T. M. Williams, and R. F. Siliciano. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. *J. Virol.* 81:2508-2518.
- Boutwell, C. L., C. F. Rowley, and M. Essex. 2009. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. *J. Virol.* 83:2460-2468.
- Brockman, M. A., A. Schneidewind, M. Lahaie, A. Schmidt, T. Miura, I. Desouza, F. Ryvkin, C. A. Derdeyn, S. Allen, E. Hunter, J. Mulenga, P. A. Goepfert, B. D. Walker, and T. M. Allen. 2007. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. *J. Virol.* 81:12608-12618.
- Brockman, M. A., G. O. Tanzi, B. D. Walker, and T. M. Allen. 2006. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. *J. Virol. Methods* 131:134-142.
- Brumme, Z. L., C. J. Brumme, J. Carlson, H. Streeck, M. John, Q. Eichbaum, B. L. Block, B. Baker, C. Kadie, M. Markowitz, H. Jessen, A. D. Kelleher, E. Rosenberg, J. Kaldor, Y. Yuki, M. Carrington, T. M. Allen, S. Mallal, M. Altfeld, D. Heckerman, and B. D. Walker. 2008. Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. *J. Virol.* 82:9216-9227.
- Brumme, Z. L., C. J. Brumme, D. Heckerman, B. T. Korber, M. Daniels, J. Carlson, C. Kadie, T. Bhattacharya, C. Chui, J. Szinger, T. Mo, R. S. Hogg, J. S. Montaner, N. Frahm, C. Brander, B. D. Walker, and P. R. Harrigan. 2007. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. *PLoS Pathog.* 3:e94.
- Campbell, T. B., K. Schneider, T. Wrin, C. J. Petropoulos, and E. Connick. 2003. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. *J. Virol.* 77:12105-12112.
- Chin, B. S., J. Choi, J. G. Nam, M. K. Kee, S. D. Suh, J. Y. Choi, C. Chu, and S. S. Kim. 2006. Inverse relationship between viral load and genotypic resistance mutations in Korean patients with primary HIV type 1 infections. *AIDS Res. Hum. Retroviruses* 22:1142-1147.
- Chopera, D. R., Z. Woodman, K. Mlisana, M. Mlotshwa, D. P. Martin, C. Seoghe, F. Treurnicht, D. A. de Rosa, W. Hide, S. A. Karim, C. M. Gray, and C. Williamson. 2008. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. *PLoS Pathog.* 4:e1000033.
- Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. Crowe, A. Maerz, S. Sonza, J. Learmont, J. S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton, and J. Mills. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. *Science* 270:988-991.
- Deeks, S. G., R. Hoh, T. B. Neillands, T. Liegler, F. Aweeka, C. J. Petropoulos, R. M. Grant, and J. N. Martin. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. *J. Infect. Dis.* 192:1537-1544.
- Deeks, S. G., and B. D. Walker. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. *Immunity* 27:406-416.
- Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambek, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. *J. Biol. Chem.* 279:509-516.
- Draenert, R., S. Le Gall, K. J. Pfafferott, A. J. Leslie, P. Chetty, C. Brander, E. C. Holmes, S. C. Chang, M. E. Feeney, M. M. Addo, L. Ruiz, D. Ramduth, P. Jeena, M. Altfeld, S. Thomas, Y. Tang, C. L. Verrill, C. Dixon, J. G. Prado, P. Kiepiela, J. Martinez-Picado, B. D. Walker, and P. J. Goulder. 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. *J. Exp. Med.* 199:905-915.
- Emu, B., E. Sinclair, H. Hatano, A. Ferre, B. Shacklett, J. N. Martin, J. M. McCune, and S. G. Deeks. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. *J. Virol.* 82:5398-5407.
- Feeney, M. E., Y. Tang, K. Pfafferott, K. A. Roosevelt, R. Draenert, A. Trocha, X. G. Yu, C. Verrill, T. Allen, C. Moore, S. Mallal, S. Burchett, K. McIntosh, S. I. Pelton, M. A. St. John, R. Hazra, P. Klenerman, M. Altfeld, B. D. Walker, and P. J. Goulder. 2005. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. *J. Immunol.* 174:7524-7530.
- Frahm, N., S. Adams, P. Kiepiela, C. H. Linde, H. S. Hewitt, M. Lichterfeld, K. Sango, N. V. Brown, E. Pae, A. G. Wurcel, M. Altfeld, M. E. Feeney, T. M. Allen, T. Roach, M. A. St. John, E. S. Daar, E. Rosenberg, B. Korber, F. Marincola, B. D. Walker, P. J. Goulder, and C. Brander. 2005. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is

- associated with low human immunodeficiency virus load. *J. Virol.* **79**:10218–10225.
24. Goepfert, P. A., W. Lumpp, P. Farmer, P. Matthews, A. Prendergast, J. M. Carlson, C. A. Derdeyn, J. Tang, R. A. Kaslow, A. Bansal, K. Yusim, D. Heckerman, J. Mulenga, S. Allen, P. J. Goulder, and E. Hunter. 2008. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. *J. Exp. Med.* **205**:1009–1017.
 25. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. *Nat. Med.* **3**:212–217.
 26. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. *J. Virol.* **72**:3773–3778.
 27. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. *J. Virol.* **70**:5930–5934.
 28. Hecht, F. M., L. Wang, A. Collier, S. Little, M. Markowitz, J. Margolick, J. M. Kilby, E. Daar, B. Conway, and S. Holte. 2006. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. *J. Infect. Dis.* **194**:725–733.
 29. Honeyborne, I., A. Prendergast, F. Pereyra, A. Leslie, H. Crawford, R. Payne, S. Reddy, K. Bishop, E. Moodley, K. Nair, M. van der Stok, N. McCarthy, C. M. Rousseau, M. Addo, J. I. Mullins, C. Brander, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8⁺ T-cell epitopes. *J. Virol.* **81**:3667–3672.
 30. Jeeninga, R. E., W. Keulen, C. Boucher, R. W. Sanders, and B. Berkhout. 2001. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. *Virology* **283**:294–305.
 31. Kassutto, S., K. Maghsoudi, M. N. Johnston, G. K. Robbins, N. C. Burgett, P. E. Sax, D. Cohen, E. Pae, B. Davis, K. Zachary, N. Basgog, E. M. D'Agata, V. DeGruttola, B. D. Walker, and E. S. Rosenberg. 2006. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. *Clin. Infect. Dis.* **42**:1024–1031.
 32. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K. J. Pfafferoth, L. Hilton, P. Zimbwa, S. Moore, T. Allen, C. Brander, M. M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L. D. Barber, J. Szinger, C. Day, P. Klenerman, J. Mullins, B. Korber, H. M. Coovadia, B. D. Walker, and P. J. Goulder. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. *Nature* **432**:769–775.
 33. Kilby, J. M., H. Y. Lee, J. D. Hazelwood, A. Bansal, R. P. Bucy, M. S. Saag, G. M. Shaw, E. P. Acosta, V. A. Johnson, A. S. Perelson, and P. A. Goepfert. 2008. Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. *AIDS* **22**:957–962.
 34. Kirchhoff, F., T. C. Greenough, D. B. Brettler, J. L. Sullivan, and R. C. Desrosiers. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. *N. Engl. J. Med.* **332**:228–232.
 35. Lassen, K. G., M. A. Lobritz, J. R. Bailey, S. Johnston, S. Nguyen, B. Lee, T. Chou, R. F. Siliciano, M. Markowitz, and E. J. Arts. 2009. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. *PLoS Pathog.* **5**:e1000377.
 36. Leslie, A. J., K. J. Pfafferoth, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes, T. Allen, J. G. Prado, M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S. A. Thomas, A. St. John, T. A. Roach, B. Kupfer, G. Luzzi, A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli, J. Martinez-Picado, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2004. HIV evolution: CTL escape mutation and reversion after transmission. *Nat. Med.* **10**:282–289.
 37. Little, S. J., S. D. Frost, J. K. Wong, D. M. Smith, S. L. Pond, C. C. Ignacio, N. T. Parkin, C. J. Petropoulos, and D. D. Richman. 2008. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. *J. Virol.* **82**:5510–5518.
 38. Maeda, Y., D. J. Venzon, and H. Mitsuya. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. *J. Infect. Dis.* **177**:1207–1213.
 39. Martinez-Picado, J., and M. A. Martinez. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. *Virus Res.* **134**:104–123.
 40. Martinez-Picado, J., J. G. Prado, E. E. Fry, K. Pfafferoth, A. Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, T. Pillay, C. Rousseau, J. I. Mullins, C. Brander, B. D. Walker, D. I. Stuart, P. Kiepiela, and P. Goulder. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J. Virol.* **80**:3617–3623.
 41. Martinez-Picado, J., A. V. Savara, L. Shi, L. Sutton, and R. T. D'Aquila. 2000. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. *Virology* **275**:318–322.
 42. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. *J. Virol.* **73**:3744–3752.
 43. Migueles, S. A., A. C. Laborico, H. Imamichi, W. L. Shupert, C. Royce, M. McLaughlin, L. Ehler, J. Metcalf, S. Liu, C. W. Hallahan, and M. Connors. 2003. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. *J. Virol.* **77**:6889–6898.
 44. Miura, T., M. A. Brockman, C. J. Brumme, Z. L. Brumme, J. M. Carlson, F. Pereyra, A. Trocha, M. M. Addo, B. L. Block, A. C. Rothchild, B. M. Baker, T. Flynn, A. Schneidewind, B. Li, Y. E. Wang, D. Heckerman, T. M. Allen, and B. D. Walker. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. *J. Virol.* **82**:8422–8430.
 45. Miura, T., M. A. Brockman, Z. L. Brumme, C. J. Brumme, F. Pereyra, A. Trocha, B. L. Block, A. Schneidewind, T. M. Allen, D. Heckerman, and B. D. Walker. 2009. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. *J. Virol.* **83**:140–149.
 46. Miura, T., M. A. Brockman, A. Schneidewind, M. Lobritz, F. Pereyra, A. Rathod, B. L. Block, Z. L. Brumme, C. J. Brumme, B. Baker, A. C. Rothchild, B. Li, A. Trocha, E. Cutrell, N. Frahm, C. Brander, I. Toth, E. J. Arts, T. M. Allen, and B. D. Walker. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. *J. Virol.* **83**:2743–2755.
 47. O'Brien, S. J., X. Gao, and M. Carrington. 2001. HLA and AIDS: a cautionary tale. *Trends Mol. Med.* **7**:379–381.
 48. Pereyra, F., M. M. Addo, D. E. Kaufmann, Y. Liu, T. Miura, A. Rathod, B. Baker, A. Trocha, R. Rosenberg, E. Mackey, P. Ueda, Z. Lu, D. Cohen, T. Wrin, C. J. Petropoulos, E. S. Rosenberg, and B. D. Walker. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. *J. Infect. Dis.* **197**:563–571.
 49. Quinn, T. C., M. J. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, M. O. Meehan, T. Lutalo, and R. H. Gray. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N. Engl. J. Med.* **342**:921–929.
 50. Quinones-Mateu, M. E., S. C. Ball, A. J. Marozsan, V. S. Torre, J. L. Albright, G. Vanham, G. van Der Groen, R. L. Colebunders, and E. J. Arts. 2000. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. *J. Virol.* **74**:9222–9233.
 51. Ross, L., N. Parkin, and R. Lanier. 2008. The number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility. *AIDS Res. Hum. Retroviruses* **24**:617–620.
 52. Saez-Cirion, A., C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. Boufassa, F. Barre-Sinoussi, J. F. Delfraissy, M. Sinet, G. Pancino, and A. Venet. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. *Proc. Natl. Acad. Sci. U. S. A.* **104**:6776–6781.
 53. Schneidewind, A., M. A. Brockman, R. Yang, R. I. Adam, B. Li, S. Le Gall, C. R. Rinaldo, S. L. Craggs, R. L. Allgaier, K. A. Power, T. Kuntzen, C.-S. Tung, M. X. Labute, S. M. Mueller, T. Harrer, A. J. McMichael, P. J. R. Goulder, C. Aiken, C. Brander, A. D. Kelleher, and T. M. Allen. 2007. Escape from the dominant HLA-B27 restricted CTL response in Gag is associated with a dramatic reduction in HIV-1 replication. *J. Virol.* **81**:12382–12393.
 54. Schneidewind, A., Y. Tang, M. A. Brockman, E. G. Ryland, J. Dunkley-Thompson, J. C. Steel-Duncan, M. A. St. John, J. A. Conrad, S. A. Kalams, F. Noel, T. M. Allen, C. D. Christie, and M. E. Feeney. 2009. Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant. *J. Virol.* **83**:8616–8627.
 55. Troyer, R. M., K. R. Collins, A. Abraha, E. Fraundorf, D. M. Moore, R. W. Krizan, Z. Toossi, R. L. Colebunders, M. A. Jensen, J. I. Mullins, G. Vanham, and E. J. Arts. 2005. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. *J. Virol.* **79**:9006–9018.
 56. Villena, C., J. G. Prado, M. C. Puertas, M. A. Martinez, B. Clotet, L. Ruiz, N. T. Parkin, L. Menendez-Arias, and J. Martinez-Picado. 2007. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. *J. Virol.* **81**:4713–4721.

57. **Weber, J., B. Chakraborty, J. Weberova, M. D. Miller, and M. E. Quinones-Mateu.** 2005. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. *J. Clin. Microbiol.* **43**:1395–1400.
58. **White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger.** 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. *Antimicrob. Agents Chemother.* **46**:3437–3446.
59. **Yoshimura, K., R. Feldman, E. Kodama, M. F. Kavlick, Y. L. Qiu, J. Zembicka, and H. Mitsuya.** 1999. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylencyclopropane nucleoside analogues. *Antimicrob. Agents Chemother.* **43**:2479–2483.
60. **Zimmer, J. M., F. Roman, C. Lambert, A. Jonckheer, A. Vazquez, J. M. Plessier, J. Y. Servais, K. Covens, J. Weber, K. Van Laethem, J. C. Schmit, A. M. Vandamme, M. E. Quinones-Mateu, and M. De Maeyer.** 2008. Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. *J. Acquir. Immune Defic. Syndr.* **48**:255–262.

Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters^{∇†}

Jaclyn K. Wright,¹ Zabrina L. Brumme,^{2,3} Jonathan M. Carlson,⁴ David Heckerman,⁴ Carl M. Kadie,⁴ Chanson J. Brumme,³ Bingxia Wang,⁵ Elena Losina,⁵ Toshiyuki Miura,⁶ Fundisiwe Chonco,¹ Mary van der Stok,¹ Zenele Mncube,¹ Karen Bishop,¹ Philip J. R. Goulder,^{1,7,8} Bruce D. Walker,^{1,8,9} Mark A. Brockman,^{2,3} and Thumbi Ndung'u^{1,8*}

*HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa*¹; *Simon Fraser University, Burnaby, Canada*²; *BC Centre for Excellence in HIV/AIDS, Vancouver, Canada*³; *eScience Group, Microsoft Research, Redmond, Washington*⁴; *Program in HIV Outcomes Research, Massachusetts General Hospital, Boston, Massachusetts*⁵; *Institute of Medical Science, University of Tokyo, Tokyo, Japan*⁶; *Department of Paediatrics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom*⁷; *Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts*⁸; and *Howard Hughes Medical Institute, Chevy Chase, Maryland*⁹

Received 19 May 2010/Accepted 29 July 2010

The mechanisms underlying HIV-1 control by protective HLA class I alleles are not fully understood and could involve selection of escape mutations in functionally important Gag epitopes resulting in fitness costs. This study was undertaken to investigate, at the population level, the impact of HLA-mediated immune pressure in Gag on viral fitness and its influence on HIV-1 pathogenesis. Replication capacities of 406 recombinant viruses encoding plasma-derived Gag-protease from patients chronically infected with HIV-1 subtype C were assayed in an HIV-1-inducible green fluorescent protein reporter cell line. Viral replication capacities varied significantly with respect to the specific HLA-B alleles expressed by the patient, and protective HLA-B alleles, most notably HLA-B*81, were associated with lower replication capacities. HLA-associated mutations at low-entropy sites, especially the HLA-B*81-associated 186S mutation in the TL9 epitope, were associated with lower replication capacities. Most mutations linked to alterations in replication capacity in the conserved p24 region decreased replication capacity, while most in the highly variable p17 region increased replication capacity. Replication capacity also correlated positively with baseline viral load and negatively with baseline CD4 count but did not correlate with the subsequent rate of CD4 decline. In conclusion, there is evidence that protective HLA alleles, in particular HLA-B*81, significantly influence Gag-protease function by driving sequence changes in Gag and that conserved regions of Gag should be included in a vaccine aiming to drive HIV-1 toward a less fit state. However, the long-term clinical benefit of immune-driven fitness costs is uncertain given the lack of correlation with longitudinal markers of disease progression.

There is broad heterogeneity in the ability of HIV-infected individuals to control virus replication, ranging from elite controllers, who maintain undetectable viral loads without treatment, to rapid progressors, who progress to AIDS within 2 years of infection (9, 22, 32). Many interrelated factors, including host and viral genetic factors involved in antiviral immunity and the viral life cycle, may partially account for the differences in the course of disease progression (10, 11, 30, 41). The complex interplay between host genetic factors and viral factors is exemplified by human leukocyte antigen (HLA) class I-restricted cytotoxic T-lymphocyte (CTL) responses, which exert considerable immune pressure on the virus, resulting in

escape mutations that affect the interaction of viral and host proteins, thereby influencing infection outcome.

The exact mechanisms by which some HLA class I alleles, such as HLA-B*57 and HLA-B*27, are associated with slower progression to AIDS, while others, such as B*5802 and B*18, are associated with accelerated disease progression (6, 20, 42), are unclear. The magnitude and/or breadth of HLA-restricted CTL responses to the conserved Gag protein has been correlated inversely with disease progression or markers of disease progression in several studies (12, 21, 28, 31, 35, 43, 46), although there are some exceptions (4, 16, 37), while preferential targeting of the highly variable envelope protein (as occurs in HLA-B*5802-positive individuals) correlates with higher viral loads (21, 29). Protective HLA alleles restrict CTL responses that impose a strong selection pressure on a few specific Gag p24 epitopes, resulting in escape mutations (14) for which fitness costs have been demonstrated either through site-directed mutations introduced into a reference strain background (2, 8, 25, 38) or through *in vivo* reversion of these mutations after transmission to an HLA-mismatched individ-

* Corresponding author. Mailing address: HIV Pathogenesis Programme, University of KwaZulu-Natal, 719 Umbilo Road, Durban 4013, South Africa. Phone: 27 31 260 4727. Fax: 27 31 260 4623. E-mail: ndungu@ukzn.ac.za.

† Supplemental material for this article may be found at <http://jvi.asm.org/>.

[∇] Published ahead of print on 11 August 2010.

ual (8, 24). Recent evidence suggests that Gag escape mutations with a fitness cost, particularly those in p24, are a significant determinant of disease progression: the transmitted number of HLA-B-associated polymorphisms in Gag was found to significantly impact the viral set point in recipients (although an associated fitness cost was not shown) (7, 15), and in a small number of infants, decreased fitness of the transmitted virus with HLA-B*5703/5801-selected mutations in Gag p24 epitopes resulted in slower disease progression (33, 39). Also, the number of reverting Gag mutations (thought to revert as a consequence of fitness costs) associated with individual HLA-B alleles was strongly correlated with the HLA-linked viral set point in chronically infected patients (26). A recent *in vitro* study showed that HLA-associated variation in Gag-protease, with resulting reduced replication capacity, may contribute to viral control in HIV-1 subtype B-infected elite controllers (27). Taken together, these studies suggest that CTL responses restricted by favorable HLA alleles select for escape mutations in conserved epitopes, particularly those in Gag, resulting in a fitness cost to HIV and therefore at least partly explaining the slower disease progression in individuals carrying these alleles.

To date, many of the studies investigating the fitness cost of Gag escape mutations and their clinical relevance have concentrated on escape mutations associated with protective HLA alleles, have not assessed fitness consequences in the natural sequence background (in the presence of other escape and compensatory mutations), and/or have focused on a limited number of patients. Most importantly, the majority of studies have focused on HIV-1 subtype B. The present study is the first to use a large population-based approach and clinically derived Gag-protease sequences to investigate comprehensively the relationships between immune-driven sequence variation in Gag, viral replication capacity, and markers of disease progression in chronic infection with HIV-1 subtype C, the most predominant subtype in the epidemic. We assayed the replication capacity of recombinant viruses encoding patient Gag-protease in an HIV-1-inducible green fluorescent protein (GFP) reporter cell line and found associations between lower replication capacities, protective HLA alleles, protective HLA-associated mutations, lower baseline viral loads, and higher baseline CD4 counts. However, Gag-protease replication capacity did not correlate with the subsequent rate of CD4 decline.

MATERIALS AND METHODS

Study subjects. The study subjects included 406 antiretroviral-naïve individuals chronically infected with HIV-1 subtype C from the Sinikithemba cohort in Durban, South Africa. These individuals were HLA typed to 4-digit resolution by molecular methods (20). Viral load (Roche Amplicor assay, version 1.5) and CD4 count (Trucount technology) measurements were obtained at study entry (baseline) for all participants and at 3-month intervals thereafter for 339 of the participants (20). At baseline, the median viral load of the cohort was 4.77 log₁₀ HIV RNA copies/ml (interquartile range [IQR], 4.15 to 5.27 log₁₀ HIV RNA copies/ml), and the median CD4 count was 340 cells/mm³ (IQR, 238 to 477 cells/mm³). Over the subsequent course of study follow-up (the mean follow-up time was 2.28 years per individual; IQR, 1.21 to 3.02 years), the median rate of CD4 decline was -30 cells/mm³ per year (IQR, -73 to -3 cells/mm³ per year). The median age of the study subjects at baseline was 31 years (IQR, 27 to 36 years), and 322 (79%) patients were female. Among the study participants, there was no significant association between age, gender, and baseline viral load or CD4 count as was reported previously (42), and therefore we did not control for

these variables in analyses. Written informed consent was obtained from all study subjects, and the study protocol was approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal.

Generation of Gag-protease NL4-3 recombinant virus stocks. Patient Gag-protease was isolated and inserted into an NL4-3 backbone to generate recombinant viruses. Protease was included to maintain the important interaction between Gag and protease, namely, cleavage of the Gag polyprotein by protease. Viral RNA was isolated from plasma by use of a QIAamp Viral RNA Mini kit from Qiagen (Valencia). Reverse transcription-PCR (RT-PCR) was performed as previously described (27), using a Superscript III One-Step RT-PCR kit (Invitrogen, Carlsbad, CA) and the following Gag-protease-specific primers: 5' CAC TGC TTA AGC CTC AAT AAA GCT TGC C 3' (HXB2 nucleotides 512 to 539) and 5' TTT AAC CCT GCT GGG TGT GGT ATY CCT 3' (nucleotides 2851 to 2825). A second round of PCR was performed with 100-mer forward and reverse primers that were exactly complementary to NL4-3 on either side of Gag-protease, using a TaKaRa Ex Taq HS enzyme kit (Takara, Shiga, Japan). Two 50- μ l PCR mixtures were prepared for each sample, comprising 37 μ l diethyl pyrocarbonate (DEPC)-treated water, 5 μ l 10 \times Ex Taq buffer, 4 μ l of deoxynucleoside triphosphates (dNTPs), 0.8 μ l forward primer (10 μ M), 0.8 μ l reverse primer (10 μ M), 0.25 μ l Ex Taq, and 2 μ l RT-PCR product. Thermocycler conditions were as follows: 94°C for 2 min; 40 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 2 min; and 72°C for 7 min. PCR products from two 50- μ l reaction mixtures were pooled, and 10 μ l was set aside for sequencing. The remainder was used in the generation of recombinant viruses. Gag-protease-deleted pNL4-3 plasmid was prepared as previously described (27), and large stocks of the plasmid were generated using a Plasmid Maxi kit (Qiagen, Valencia, CA). The plasmid was digested for 2 h at 60°C immediately prior to cotransfection of 2 \times 10⁶ Tat-inducible GFP reporter GXR T cells (3) in R10 medium (800 μ l RPMI-1640 [Sigma, St. Louis, MO] supplemented with 10% fetal bovine serum [Gibco, NY], 2 mM L-glutamine [Sigma], 10 mM HEPES [Gibco], and 50 U/ml penicillin-streptomycin [Gibco]) with 10 μ g digested plasmid and \approx 85 μ l Gag-protease PCR product via electroporation at 300 V and 500 μ F (27). Following a 1-h incubation at room temperature, GXR cells were transferred to T25 flasks containing 4 ml of medium each. Five days later, 5 ml R10 medium was added to each flask. The percentage of infected cells was monitored from day 12 onwards by flow cytometry on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Culture supernatants were harvested when approximately 30% of the GXR cells were infected and were stored in 1-ml aliquots at -80°C for use in subsequent titration and replication assays.

Titration and replication assays. Titration of virus stocks and replication assays were performed as previously described (2, 27, 38), using a multiplicity of infection (MOI) of 0.003. The mean slope of exponential growth from days 3 to 6 was calculated using the semilog method in Excel. This was divided by the slope of growth of the wild-type NL4-3 control included in each assay to generate a normalized measure of replication capacity. Replication assays were performed at least in duplicate, and results were averaged.

Sequencing of Gag-protease gene. The Gag-protease PCR product was diluted 1:15 in DEPC-treated water and population sequenced using Big Dye Terminator ready reaction mix V3 (Applied Biosystems, Foster City, CA) and the following sequencing primers: 5' CTT GTC TAG GGC TTC CTT GGT 3' (nucleotides 1098 to 1078), 5' CTT CAG ACA GGA ACA GAG GA 3' (nucleotides 991 to 1010), 5' GGT TCT CTC ATC TGG CCT GG 3' (nucleotides 1481 to 1462), 5' CAA CAA GGT TTC TGT CAT CC 3' (nucleotides 1755 to 1736), 5' CCT TGC CAC AGT TGA AAC ATT T 3' (nucleotides 1981 to 1960), 5' TAG AAG AAA TGA TGA CAG 3' (nucleotides 1817 to 1834), 5' CAG CCA AGC TGA GTC AA 3' (nucleotides 2536 to 2520), and 5' GGA GCA GAT GAT ACA GTA TT 3' (nucleotides 2331 to 2350). Sequences were analyzed on an ABI 3130xl genetic analyzer (Applied Biosystems) and were visualized and edited in Sequencher 4.8. Sequence data were aligned with the sequence of HIV-1 subtype B reference strain HXB2 (GenBank accession no. K03455), using a modified NAP algorithm (18), and insertions with respect to the HXB2 sequence were stripped from the sequences. A neighbor-joining tree was constructed from nucleotide sequences by using Paup 4.0 and was edited in Figtree (<http://tree.bio.ed.ac.uk/software/figtree/>). Nucleotide differences between plasma and recombinant virus Gag-protease sequences were quantified using Highlighter (<http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html>). BioEdit 7.0 (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>) was used to calculate the similarity of each sequence to the consensus subtype C Gag sequence from 2004.

Identification of HLA-associated polymorphisms. Statistical methods (described in detail in reference 5) that correct for phylogenetic relatedness between HIV sequences, amino acid covariation, and HLA linkage disequilibrium effects were used to identify HLA-associated polymorphisms. Briefly, a maximum like-

likelihood phylogenetic tree was constructed for each gene, and a model of conditional adaptation was inferred for each observed amino acid at each codon. In this model, the amino acid is assumed to evolve independently down the phylogeny, until it reaches the observed sequences at the tree tips. In each host, the selection pressure arising from HLA-restricted CTL and covariation between HIV codons is modeled directly by a stochastic additive process. To identify which factors contribute to the observed sequences, a forward selection procedure is employed, in which the most significant association is iteratively added to the model, with P values computed using the likelihood ratio test. Each observed amino acid variant at each codon is evaluated in a binary fashion (presence versus absence thereof). Multiple tests are addressed using q values, the P value analogue of the false discovery rate (FDR), for each P value threshold (40). The FDR is the expected proportion of false-positive results among results deemed significant at a given threshold. For example, at a q value of ≤ 0.2 , we would expect a false-positive proportion of 20% among identified associations.

Data analysis. Viral replication capacities were grouped according to the HLA class I alleles expressed by the host. Analysis of variance (ANOVA) was used to assess whether significant differences in replication capacities were observed within expressed HLA-A, -B, and -C alleles. Then, for each individual allele ($n \geq 5$), Student's t test (or the Mann-Whitney U test in cases where the assumptions of Student's t test were not met) was used to compare replication capacities of viruses generated from persons expressing versus not expressing the allele in question. The relationships between replication capacity and log viral load, CD4 count, rate of CD4 decline, number of HLA-associated polymorphisms, and sequence similarity to the HIV-1 subtype C Gag consensus were assessed using Pearson's correlation (for normally distributed variables) or Spearman's rank correlation (for non-normally distributed variables). Viruses were also categorized according to the 10th and 90th percentiles of the replication capacity data, into low- and high-replication-capacity groups, respectively. Clinical and sequence parameters were compared between these groups, using Student's t test (or the Mann-Whitney U test) or Fisher's exact test (in the case of proportion comparisons). The association between single amino acid residues in Gag-protease and the replication capacity was analyzed by Mann-Whitney U tests (univariate method) and linear regression with a forward selection process (multivariate method). q values were calculated in both cases to account for multiple comparisons (40). The significance cutoff for all analyses, unless indicated otherwise, was a P value of < 0.05 .

Nucleotide sequence accession numbers. Gag-protease sequences obtained in this study are available in the GenBank database under accession numbers HM593106 to HM593510.

RESULTS

Validation of generated Gag-protease NL4-3 recombinant viruses. Gag-protease NL4-3 recombinant virus stocks from 406 subjects were generated in a median of 27 days (IQR, 23 to 32 days) following cotransfection of HIV-inducible, GFP-expressing T cells with Gag-protease-deleted NL4-3 plasmid and clinically derived Gag-protease amplicons. To test whether recombinant viruses were representative of the original plasma quasispecies, Gag-protease was resequenced from 40 randomly selected recombinant viruses and compared with the original plasma HIV RNA sequences. The median number of total nucleotide differences between the recombinant virus sequence and the original plasma HIV RNA sequence (when mixtures were not included as differences) was 0 (IQR, 0 to 1.5), resulting in an average nucleotide similarity of 0.99% between pairs. The average number of nucleotide mixtures in recombinant virus sequences was 21 (standard deviation [SD] = 17), indicating somewhat reduced diversity (Student's t test; $P = 0.0002$) compared to that of the original plasma sequences (mean = 35; SD = 36). Recombinant virus Gag sequences closely clustered with respective plasma Gag sequences in a phylogenetic tree (see Fig. SA1 in the supplemental material). These data indicate that the Gag-protease recombinant viruses were representative of the original plasma




FIG. 1. Distribution of Gag-protease NL4-3 recombinant virus replication capacities, normalized to the growth of wild-type NL4-3.

quasispecies. All further analyses were based on the original plasma HIV sequences.

Assay variability. The replication capacities of Gag-protease NL4-3 recombinant viruses were assayed in duplicate, independently, in an HIV-1-inducible GFP reporter cell line. Replication capacity was defined as the slope of the increase in the percentage of infected cells from days 3 to 6 following infection, normalized to wild-type NL4-3. Duplicate measurements were highly concordant (Pearson's correlation; $r = 0.88$ and $P < 0.0001$). Accuracy of recombinant viral titers was achieved: on day 3 of the assay, the mean % GFP-expressing cells was 0.65% (SD = 0.28%). Importantly, the observed variability in day 3 readings did not influence viral replication capacity measurements (Pearson's correlation; $r = 0.04$ and $P = 0.44$).

Distribution of replication capacities of recombinant viruses. The NL4-3-normalized replication capacities of the recombinant viruses generated from the 406 cohort participants approximated a normal distribution (mean = 0.62; SD = 0.1) (Fig. 1). The replication capacities of the recombinant HIV-1 subtype C Gag-protease sequences inserted into the NL4-3 backbone were considerably lower than those of the wild-type NL4-3 control and 25 subtype B Gag-protease NL4-3 recombinant viruses, whose mean replication capacity normalized to wild-type NL4-3 was 0.95 (SD = 0.13) (data not shown).

Association of recombinant virus replication capacities with specific HLA types. Replication capacities of recombinant viruses were grouped according to HLA alleles expressed by the host (Fig. 2). Overall, replication capacities varied significantly between the different HLA-B alleles (ANOVA; $P = 0.01$) but not between HLA-A or HLA-C alleles, suggesting that HLA-B alleles have the greatest impact on Gag-protease-mediated replication capacity. Relationships between specific HLA alleles and replication capacity were also observed, the strongest of which was the association of HLA-B*81 with lower replication capacities (Student's t test; $P < 0.0001$). P values presented are uncorrected for multiple comparisons. Only the association of HLA-B*81 with lower replication capacities




FIG. 2. Associations between HLA alleles and replication capacities of Gag-protease NL4-3 recombinant viruses. (A to C)-Graphs show the mean (dot), median (vertical line), interquartile range (edges of boxes), and most extreme values (edges of whiskers) of replication capacities for each different HLA allele for which $n \geq 5$. *, individual significant ($P < 0.05$) associations (Student's t test); **, associations that survive Bonferroni correction for multiple comparisons. Overall P values (ANOVA) indicate the significance of differences in replication capacity between alleles of each group. (D) Graph showing a significantly greater proportion (Fisher's exact test) of individuals with protective HLA alleles (HLA-B*57, HLA-B*5801, and HLA-B*81) in the group with the least-fit viruses (replication capacity of ≤ 0.5 ; $n = 41$) than in the group with the fittest viruses (replication capacity of ≥ 0.74 ; $n = 41$).

would remain statistically significant following Bonferroni adjustment for multiple comparisons.

Besides HLA-B*81, other alleles that were associated with low-replication-capacity recombinant viruses were HLA-B*5801, HLA-A*0205 (Mann-Whitney U test; $P = 0.05$ and $P = 0.04$, respectively), HLA-A*3009, and HLA-A*3001 (Student's t test; $P = 0.02$ and $P = 0.05$, respectively). Due to tight linkage between HLA-B*5801 and HLA-A*0205 ($D' = 0.56$ [23]), the allele driving the effect could not be identified. Among 5 individuals with HLA-B*3009, 4 possessed HLA-B*81, which likely explains the association of HLA-B*3009 with lower replication capacities.

Alleles associated with higher replication capacities were HLA-Cw*0702 (Student's t test; $P = 0.05$) and HLA-Cw*0501 (Mann-Whitney U test; $P = 0.001$). Only 6 individuals in this

study possessed HLA-Cw*0501, and all were linked to replication capacities above the 80th percentile of the data set (> 0.7). HLA-Cw*0501 is in linkage disequilibrium with HLA-B*1801—5 of 6 individuals with HLA-Cw*0501 also carried HLA-B*1801—and could therefore partly contribute to the disadvantage associated with HLA-B*1801 in subtype C infection (20).

In an additional analysis, the HLA types of the individuals corresponding to the fittest recombinant viruses (≥ 90 th percentile of the data set, i.e., ≥ 0.74 ; $n = 41$) were compared to the HLA types of individuals with the least-fit recombinant viruses (10th percentile of the data set, i.e., ≤ 0.5 ; $n = 41$). Protective alleles were defined as those that were most strongly associated with lower viral loads in HIV-1 subtype C-infected individuals, namely, HLA-B*57, HLA-B*5801, and HLA-